Abstract
This study was aimed to correlate the pre- and 6-month postpercutaneous coronary intervention
(PCI) serum concentrations of advanced glycation end products (AGE), soluble receptors
for advanced glycation end products (sRAGE), AGE/sRAGE ratio, and serum malondialdehyde
(MDA) levels with in-stent restenosis (ISR) among patients receiving either a drug-eluting
stent (DES) or a bare-metal stent (BMS).In-stent restenosis remains as an adverse
outcome following PCI. Sixty consecutive nondiabetic, Caucasian male patients, diagnosed
with a non-ST-elevation myocardial infarction who received either a DES or BMS via
PCI, were enrolled. Baseline levels of serum AGE, sRAGE, AGE/sRAGE ratios, MDA, and
angiographic parameters were determined at stenting and at 6 months. Patients with
and without ISR at 6 months were compared on both baseline and 6-month biomarker levels
and within stent types.The pre-PCI serum AGE levels and AGE/sRAGE ratios were higher
in ISR patients compared with non-ISR patients, while the pre-PCI and post-PCI serum
sRAGE levels were lower in ISR patients compared with non-ISR patients. The pre and
post-PCI levels of MDA were also higher in ISR patients. Comparing stent types, relative
levels of MDA between those with and without ISR at the respective time points were
similar, although changes between time points appeared type specific.Post-PCI ISR
correlates with low serum values of sRAGE and high serum values of AGE, MDA, and AGE/sRAGE
ratio which are present at stenting. The associations of baseline AGE, sRAGE, AGE/sRAGE,
and MDA levels with ISR appear consistent between stent types.
Keywords
PCI - stent - restenosis - cardiac Biomarkers - advancedglycation end products - soluble
receptor for advanced glycation end products - oxidative stress
